Recursion Pharmaceuticals (RXRX) Receivables - Net (2020 - 2023)

Recursion Pharmaceuticals (RXRX) posted Receivables - Net of $7.9 million for Q3 2023, up 11.27% on a QoQ basis from $7.1 million in Q2 2023.

Recursion Pharmaceuticals (RXRX) Receivables - Net (2020 - 2023) Analysis & Trends

Recursion Pharmaceuticals' Receivables - Net history runs 4 years deep, the most recent figure standing at $7.9 million for Q3 2023.

Quarterly Receivables - Net changed N/A year-over-year to $7.9 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $7.9 million (changed N/A YoY) and the FY2021 annual result came in at $34000.0, down 78.21% from the prior year.
Receivables - Net was $7.9 million for Q3 2023 at Recursion Pharmaceuticals, up from $7.1 million in the prior quarter.
Across five years, Receivables - Net topped out at $7.9 million in Q3 2023 and bottomed at $21000.0 in Q2 2022.
A 4-year average of $1.7 million and a median of $49000.0 in 2021 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2021 — Receivables - Net tumbled 78.21% — and 2023, when it jumped 33709.52%.
Recursion Pharmaceuticals' Receivables - Net stood at $156000.0 in 2020, then tumbled by 78.21% to $34000.0 in 2021, then plunged by 38.24% to $21000.0 in 2022, then surged by 37519.05% to $7.9 million in 2023.
Business Quant data shows RXRX's Receivables - Net at $7.9 million in Q3 2023, $7.1 million in Q2 2023, and $21000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Recursion Pharmaceuticals	1.59 Bn	933.22 Mn	-6.02 Mn

Download Data